# US 2012/0251504 A1 · Pluripotent stem cells obtained from dental pulp

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251504 A1
- Document ID: US20120251504A1
- Status: Published application
- Kind: A1
- Application number: 13/386,324
- Filed: 2010-07-21
- Published: 2012-10-04
- Earliest claimed: 2009-07-21
- Assignees: Universitat Internacional de Catalunya
- Inventors: Maher Al-Atari Abou-Asi; Núria Casals Farré; Lluís Giner Tarrida; Eduardo Ferrés Padró
- Web page: https://patentgrep.com/patent/US20120251504A1

## CPC

- C12N 5/0664: {Dental pulp stem cells, Dental follicle stem cells}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 19/00: Drugs for skeletal disorders
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2501/135: Platelet-derived growth factor [PDGF]
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pluripotent stem cells obtained from the dental pulp of patients of different ages, the invention furthermore comprises cultures of said cells, means for obtaining them and pharmaceutical compositions comprising them, as well as their application in tissue regeneration.

## Claims

### Claim 1

A pluripotent stem cell, characterized in that it is obtained from dental pulp and expresses at least the genes NANOG, SOX2, and expresses the markers SSEA4, OCT3/4 and CD105.

### Claim 2 (depends on 1)

The stem cell according to claim 1, characterized in that it additionally expresses the markers CD13, CMyc and CD90 and does not express the markers CD34, CD45, CD73 and CD44.

### Claim 3 (depends on 1)

The stem cell according to claim 1, characterized in that it is a human cell.

### Claim 4 (depends on 1)

The stem cell according to claim 1 with accession number DSM ACC3002 given by the institution DSMZ-Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH.

### Claim 5 (depends on 1)

A culture comprising a stem cell according to claim 1 in a culture medium comprising at least one transcription factor.

### Claim 6 (depends on 5)

The culture according to claim 5, characterized in that the medium comprises at least the growth factors EGF and PDGF, and at least the transcription factor UF.

### Claim 7 (depends on 1)

A process for obtaining a pluripotent stem cell according to claim 1, comprising the steps of:
(a) disaggregating the tissue of the dental pulp isolated from a mammal;
(b) separating the stem cells from the disaggregated tissue resulting from step (a); and
(c) culturing the cells in a medium having at least one transcription factor at a seeding concentration between 40-60 cells/cm2.

### Claim 8 (depends on 7)

A pluripotent stem cell obtainable by the process of claim 7.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising an effective amount of the pluripotent stem cell as defined in claim 1, and a pharmaceutically acceptable carrier.

### Claim at position 10

10-14. (canceled)

### Claim 15 (depends on 8)

A pharmaceutical composition comprising an effective amount of the pluripotent stem cell as defined in claim 8, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1)

A method for tissue regeneration or repair in mammals, which comprises administering an effective amount of the stem cell as defined in claim 1 to said mammal needing it.

### Claim 17 (depends on 16)

The method according to claim 16, for bone tissue regeneration.

### Claim 18 (depends on 16)

The method according to claim 16, for neuronal tissue regeneration.

### Claim 19 (depends on 16)

The method according to claim 16, for liver tissue regeneration.

### Claim 20 (depends on 16)

The method according to claim 16, for the in vitro manufacture of a tissue or organ.
